Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research Fraud “Fruitful” Area For Government Probes; AstraZeneca Brilinta Trial In Crosshairs

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.

You may also be interested in...



AstraZeneca Silent On Pfizer, Uses Growth And Pipeline To Speak For Its Prospects

AstraZeneca played it straight when reporting a strong second quarter, outlining a robust late stage pipeline, a growing list of early assets and collaborations, while avoiding “the elephant in the room” - predator Pfizer’s paused-pursuit of the U.K. pharma.

AstraZeneca’s Brilinta Gives Brilliant Sales Performance

AstraZeneca’s cardiovascular drug Brilinta – one of the group’s five key growth platforms - seems to have turned the corner to give a stellar performance in the second quarter – particularly in the crucial US market.

Sunshine Data Could Fast-Track False Claims Act Cases – U.S. Prosecutors

Sunshine Act penalties are relatively small but the payment disclosures could provide ammo and shortcuts for investigations into the more costly False Claims Act cases, U.S. attorneys say. On the flip side, disclosure may lead to better behavior.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel